BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U, Bioulac-Sage P, Pinzani M, Rosenbaum J, Geerts A. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut. 2004;53:1180-1189. [PMID: 15247189 DOI: 10.1136/gut.2003.036053] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Dianat N, Dubois-Pot-Schneider H, Steichen C, Desterke C, Leclerc P, Raveux A, Combettes L, Weber A, Corlu A, Dubart-Kupperschmitt A. Generation of functional cholangiocyte-like cells from human pluripotent stem cells and HepaRG cells. Hepatology. 2014;60:700-714. [PMID: 24715669 DOI: 10.1002/hep.27165] [Cited by in Crossref: 127] [Cited by in F6Publishing: 116] [Article Influence: 18.1] [Reference Citation Analysis]
2 Samonakis DN, Notas G, Christodoulakis N, Kouroumalis EA. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci. 2008;53:2359-2365. [PMID: 18273705 DOI: 10.1007/s10620-007-0175-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
3 Özgüven S, Filizoğlu N, Kesim S, Öksüzoğlu K, Şen F, Öneş T, İnanır S, Turoğlu HT, Erdil TY. Physiological Biodistribution of 68Ga-DOTA-TATE in Normal Subjects. Mol Imaging Radionucl Ther 2021;30:39-46. [PMID: 33586406 DOI: 10.4274/mirt.galenos.2021.37268] [Reference Citation Analysis]
4 Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules 2020;25:E4012. [PMID: 32887456 DOI: 10.3390/molecules25174012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
5 Abdellatif AAH, Aldalaen SM, Faisal W, Tawfeek HM. Somatostatin receptors as a new active targeting sites for nanoparticles. Saudi Pharm J 2018;26:1051-9. [PMID: 30416362 DOI: 10.1016/j.jsps.2018.05.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
6 Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol. 2007;13:3164-3170. [PMID: 17589893 DOI: 10.3748/wjg.v13.i13.3164] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Schöniger-Hekele M, Kettenbach J, Peck-Radosavljevic M, Müller C. Octreotide treatment of patients with hepatocellular carcinoma--a retrospective single centre controlled study. J Exp Clin Cancer Res 2009;28:142. [PMID: 19887008 DOI: 10.1186/1756-9966-28-142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
8 Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvanitakis M. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer. 2007;97:582-588. [PMID: 17687341 DOI: 10.1038/sj.bjc.6603901] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
9 Ji XQ, Ruan XJ, Chen H, Chen G, Li SY, Yu B. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials. Med Sci Monit. 2011;17:RA169-RA176. [PMID: 21804474 DOI: 10.12659/msm.881892] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
10 Gao J, Tong H, Huang Z, Liu R, Li X, Qiang O, Tang C. Affinity analysis of somatostatin and somatostatin receptor by surface plasmon resonance. Anal Methods 2013;5:3201. [DOI: 10.1039/c3ay26548j] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
11 Borbath I, Leclercq IA, Abarca-Quinones J, Desaeger C, Lebrun V, Moulin P, Sempoux C, Horsmans Y. Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide. Cancer Sci 2007;98:1831-9. [PMID: 17900309 DOI: 10.1111/j.1349-7006.2007.00626.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
12 Hessheimer AJ, Escobar B, Muñoz J, Flores E, Gracia-sancho J, Taurá P, Fuster J, Rimola A, García-valdecasas JC, Fondevila C. Somatostatin Therapy Protects Porcine Livers in Small-for-Size Liver Transplantation: Somatostatin Therapy in SFSS. American Journal of Transplantation 2014;14:1806-16. [DOI: 10.1111/ajt.12758] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
13 Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Gradilone SA, Huang B, Masyuk AI, Hogan MC, Torres VE, Larusso NF. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology. 2013;58:409-421. [PMID: 23172758 DOI: 10.1002/hep.26140] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 8.6] [Reference Citation Analysis]
14 Long D, Lu J, Luo L, Guo Y, Li C, Wu W, Shan J, Li L, Li S, Li Y. Effects of octreotide on activated pancreatic stellate cell-induced pancreas graft fibrosis in rats. J Surg Res. 2012;176:248-259. [PMID: 21816420 DOI: 10.1016/j.jss.2011.06.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
15 Zhang Y, Wang X, Wang J, Zhang X, Zhang Q. Octreotide-Modified Polymeric Micelles as Potential Carriers for Targeted Docetaxel Delivery to Somatostatin Receptor Overexpressing Tumor Cells. Pharm Res 2011;28:1167-78. [DOI: 10.1007/s11095-011-0381-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
16 Giglio MC, Troisi RI. Response to the Comment on "Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial". Ann Surg 2020;271:e122. [PMID: 31714314 DOI: 10.1097/SLA.0000000000003675] [Reference Citation Analysis]
17 Hessheimer AJ, Martínez de la Maza L, Adel Al Shwely F, Espinoza AS, Ausania F, Fondevila C. Somatostatin and the "Small-For-Size" Liver. Int J Mol Sci 2019;20:E2512. [PMID: 31121844 DOI: 10.3390/ijms20102512] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
18 Giglio MC, Troisi RI. Response to the Comment on "Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial". Ann Surg 2021;274:e195-6. [PMID: 31714317 DOI: 10.1097/SLA.0000000000003676] [Reference Citation Analysis]
19 Murakami K, Kumata H, Miyagi S, Kamei T, Sasano H. The prognostic significance of neuroendocrine markers and somatostatin receptor 2 in hepatocellular carcinoma. Pathol Int 2021. [PMID: 34320691 DOI: 10.1111/pin.13149] [Reference Citation Analysis]
20 Zhang X, Ng HLH, Lu A, Lin C, Zhou L, Lin G, Zhang Y, Yang Z, Zhang H. Drug delivery system targeting advanced hepatocellular carcinoma: Current and future. Nanomedicine. 2016;12:853-869. [PMID: 26772424 DOI: 10.1016/j.nano.2015.12.381] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 13.2] [Reference Citation Analysis]
21 Szepeshazi K, Schally AV, Treszl A, Seitz S, Halmos G. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin. Anti-Cancer Drugs 2008;19:349-58. [DOI: 10.1097/cad.0b013e3282f9adce] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Xia Y, Zeng C, Zhao Y, Zhang X, Li Z, Chen Y. Comparative evaluation of 68Ga-labelled TATEs: the impact of chelators on imaging. EJNMMI Res 2020;10:36. [PMID: 32297029 DOI: 10.1186/s13550-020-00620-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Pivonello C, De Martino MC, Negri M, Cuomo G, Cariati F, Izzo F, Colao A, Pivonello R. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infect Agent Cancer 2014;9:27. [PMID: 25225571 DOI: 10.1186/1750-9378-9-27] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
24 Mazzucchelli R, Morichetti D, Scarpelli M, Bono AV, Lopez-Beltran A, Cheng L, Kirkali Z, Montironi R. Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma. Asian J Androl 2011;13:242-7. [PMID: 21151154 DOI: 10.1038/aja.2010.100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
25 Massironi S, Fraquelli M, Paggi S, Sangiovanni A, Conte D, Sciola V, Ciafardini C, Colombo M, Peracchi M. Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. Dig Liver Dis. 2009;41:31-35. [PMID: 18762462 DOI: 10.1016/j.dld.2008.05.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
26 Kaemmerer D, Schindler R, Mußbach F, Dahmen U, Altendorf-Hofmann A, Dirsch O, Sänger J, Schulz S, Lupp A. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets. BMC Cancer 2017;17:896. [PMID: 29282035 DOI: 10.1186/s12885-017-3911-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
27 Vanheule E, Geerts AM, Reynaert H, Van Vlierberghe H, Geerts A, De Vos M, Colle I. Influence of somatostatin and octreotide on liver microcirculation in an experimental mouse model of cirrhosis studied by intravital fluorescence microscopy. Liver Int. 2008;28:107-116. [PMID: 18173562 DOI: 10.1111/j.1478-3231.2007.01629.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
28 Abdellatif AA, Zayed G, El-Bakry A, Zaky A, Saleem IY, Tawfeek HM. Novel gold nanoparticles coated with somatostatin as a potential delivery system for targeting somatostatin receptors. Drug Dev Ind Pharm 2016;42:1782-91. [PMID: 27032509 DOI: 10.3109/03639045.2016.1173052] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
29 Yang H, Xuefeng Y, Shandong W, Jianhua X. COX-2 in liver fibrosis. Clin Chim Acta 2020;506:196-203. [PMID: 32184095 DOI: 10.1016/j.cca.2020.03.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
30 Younis MA, Khalil IA, Harashima H. Gene Therapy for Hepatocellular Carcinoma: Highlighting the Journey from Theory to Clinical Applications. Adv Therap 2020;3:2000087. [DOI: 10.1002/adtp.202000087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Mazzucchelli R, Morichetti D, Santinelli A, Scarpelli M, Bono AV, Lopez-Beltran A, Cheng L, Montironi R. Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer. Cell Oncol (Dordr) 2011;34:235-43. [PMID: 21533650 DOI: 10.1007/s13402-011-0031-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
32 Zhang X, Yang C, Zhou J, Huo M. Somatostatin Receptor-Mediated Tumor-Targeting Nanocarriers Based on Octreotide-PEG Conjugated Nanographene Oxide for Combined Chemo and Photothermal Therapy. Small 2016;12:3578-90. [PMID: 27244649 DOI: 10.1002/smll.201600618] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
33 Abdel-Rahman O, Lamarca A, Valle JW, Hubner RA. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. Endocr Relat Cancer. 2014;21:R485-R493. [PMID: 25336571 DOI: 10.1530/erc-14-0389] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
34 Lasfer M, Vadrot N, Schally AV, Nagy A, Halmos G, Pessayre D, Feldmann G, Reyl-Desmars FJ. Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238. J Hepatol 2005;42:230-7. [PMID: 15664249 DOI: 10.1016/j.jhep.2004.10.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
35 Morichetti D, Mazzucchelli R, Stramazzotti D, Santinelli A, Lopez-beltran A, Scarpelli M, Bono AV, Cheng L, Montironi R. Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer: SOMATOSTATIN RECEPTORS IN INCIDENTAL AND CLINICAL CANCERS. BJU International 2010;106:1072-80. [DOI: 10.1111/j.1464-410x.2010.09238.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
36 Zhao Y, Peng L, Li X, Zhang Y. Expression of somatostatin and its receptor 1-5 in endometriotic tissues and cells. Exp Ther Med 2018;16:3777-84. [PMID: 30405748 DOI: 10.3892/etm.2018.6730] [Reference Citation Analysis]
37 Elnaggar MH, Abushouk AI, Hassan AHE, Lamloum HM, Benmelouka A, Moatamed SA, Abd-Elmegeed H, Attia S, Samir A, Amr N, Johar D, Zaky S. Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma. Semin Cancer Biol 2021;69:91-9. [PMID: 31421265 DOI: 10.1016/j.semcancer.2019.08.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
38 Sanoff HK, Kim R, Ivanova A, Alistar A, McRee AJ, O’Neil BH. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. Invest New Drugs. 2015;33:505-509. [PMID: 25613083 DOI: 10.1007/s10637-015-0209-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
39 Li G, Jiang Q, Xu K. CREB family: A significant role in liver fibrosis. Biochimie 2019;163:94-100. [PMID: 31112743 DOI: 10.1016/j.biochi.2019.05.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 Shastry M, Kayani I, Wild D, Caplin M, Visvikis D, Gacinovic S, Reubi JC, Bomanji JB. Distribution pattern of 68Ga-DOTATATE in disease-free patients. Nuclear Medicine Communications 2010;31:1025-32. [DOI: 10.1097/mnm.0b013e32833f635e] [Cited by in Crossref: 40] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
41 Shen M, Xu M, Zhong F, Crist MC, Prior AB, Yang K, Allaire DM, Choueiry F, Zhu J, Shi H. A Multi-Omics Study Revealing the Metabolic Effects of Estrogen in Liver Cancer Cells HepG2. Cells 2021;10:455. [PMID: 33672651 DOI: 10.3390/cells10020455] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Samonakis DN, Christodoulakis N, Kouroumalis EA. Octreotide for unresectable hepatocellular carcinoma: beyond the first sight. J Clin Gastroenterol 2006;40:86-7. [PMID: 16340641 DOI: 10.1097/01.mcg.0000190778.50279.26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
43 Guo M, Zhang H, Zheng J, Liu Y. Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma. J Cancer. 2020;11:2008-2021. [PMID: 32127929 DOI: 10.7150/jca.39972] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 22.0] [Reference Citation Analysis]
44 Sicklick JK, Li Y, Choi SS, Qi Y, Chen W, Bustamante M, Huang J, Zdanowicz M, Camp T, Torbenson MS, Rojkind M, Diehl AM. Role for Hedgehog signaling in hepatic stellate cell activation and viability. Lab Invest 2005;85:1368-80. [DOI: 10.1038/labinvest.3700349] [Cited by in Crossref: 131] [Cited by in F6Publishing: 127] [Article Influence: 8.2] [Reference Citation Analysis]
45 Reynaert H, Colle I. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature. Int J Mol Sci 2019;20:E4811. [PMID: 31569719 DOI: 10.3390/ijms20194811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
46 Rahmi G, Malka D, Tomasic G, Dromain C, Ducreux M, Boige V. Complete, Long-Standing Regression of Hepatocellular Carcinoma After Somatostatin Analogue Treatment. JCO 2007;25:e15-6. [DOI: 10.1200/jco.2006.09.5760] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
47 Turrell SJ, Whitehouse A. Mutation of herpesvirus Saimiri ORF51 glycoprotein specifically targets infectivity to hepatocellular carcinoma cell lines. J Biomed Biotechnol 2011;2011:785158. [PMID: 21197456 DOI: 10.1155/2011/785158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
48 Liu Y, Jiang L, Mu Y. Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment. Oncol Lett 2013;6:821-8. [PMID: 24137418 DOI: 10.3892/ol.2013.1435] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
49 Abdellatif AAH. Identification of somatostatin receptors using labeled PEGylated octreotide, as an active internalization. Drug Dev Ind Pharm 2019;45:1707-15. [PMID: 31418304 DOI: 10.1080/03639045.2019.1656735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Farinati F, Sergio A, Baldan A, Zucchetta P, Corleto VD. Octreotide and hepatocellular carcinoma. Br J Cancer 2007;96:1778-9. [PMID: 17505506 DOI: 10.1038/sj.bjc.6603799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
51 Abdel-Hamid NM, Mohafez OM, Nazmy MH, Farhan A, Thabet K. The effect of co-administration of Lawsonia inermis extract and octreotide on experimental hepatocellular carcinoma. Environ Health Prev Med 2015;20:195-203. [PMID: 25726025 DOI: 10.1007/s12199-015-0451-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
52 Li M, Zhang W, Wang B, Gao Y, Song Z, Zheng QC. Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma. Int J Nanomedicine 2016;11:5645-69. [PMID: 27920520 DOI: 10.2147/IJN.S115727] [Cited by in Crossref: 67] [Cited by in F6Publishing: 25] [Article Influence: 13.4] [Reference Citation Analysis]
53 Borbath I, Leclercq IA, Sempoux C, Abarca-quinones J, Desaeger C, Horsmans Y. Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. Chemico-Biological Interactions 2010;183:238-48. [DOI: 10.1016/j.cbi.2009.10.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
54 Lu YY, Gao JH, Zhao C, Wen SL, Tang CW, Wang YF. Cyclooxygenase-2 up-regulates hepatic somatostatin receptor 2 expression. Sci Rep 2018;8:11033. [PMID: 30038293 DOI: 10.1038/s41598-018-29349-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
55 Klungboonkrong V, Das D, McLennan G. Molecular Mechanisms and Targets of Therapy for Hepatocellular Carcinoma. J Vasc Interv Radiol 2017;28:949-55. [PMID: 28416267 DOI: 10.1016/j.jvir.2017.03.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
56 Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis. 2005;10:927-939. [PMID: 16151628 DOI: 10.1007/s10495-005-1055-4] [Cited by in Crossref: 294] [Cited by in F6Publishing: 287] [Article Influence: 19.6] [Reference Citation Analysis]
57 Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008;88:125-72. [PMID: 18195085 DOI: 10.1152/physrev.00013.2007] [Cited by in Crossref: 1682] [Cited by in F6Publishing: 1626] [Article Influence: 129.4] [Reference Citation Analysis]
58 Shenoy PA, Kuo A, Khan N, Gorham L, Nicholson JR, Corradini L, Vetter I, Smith MT. The Somatostatin Receptor-4 Agonist J-2156 Alleviates Mechanical Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain. Front Pharmacol 2018;9:495. [PMID: 29867498 DOI: 10.3389/fphar.2018.00495] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
59 Reynaert H, Rombouts K, Jia Y, Urbain D, Chatterjee N, Uyama N, Geerts A. Somatostatin at nanomolar concentration reduces collagen I and III synthesis by, but not proliferation of activated rat hepatic stellate cells. Br J Pharmacol. 2005;146:77-88. [PMID: 15980876 DOI: 10.1038/sj.bjp.0706298] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
60 Troisi RI, Vanlander A, Giglio MC, Van Limmen J, Scudeller L, Heyse B, De Baerdemaeker L, Croo A, Voet D, Praet M, Hoorens A, Antoniali G, Codarin E, Tell G, Reynaert H, Colle I, Sainz-barriga M. Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial. Annals of Surgery 2019;269:1025-33. [DOI: 10.1097/sla.0000000000003062] [Cited by in Crossref: 18] [Cited by in F6Publishing: 3] [Article Influence: 9.0] [Reference Citation Analysis]
61 Kumar V, Rahman M, Gahtori P, Al-Abbasi F, Anwar F, Kim HS. Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine. Expert Opin Drug Deliv 2021;18:673-94. [PMID: 33295218 DOI: 10.1080/17425247.2021.1860939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
62 Olaso E, Arteta B, Salado C, Eguilegor E, Gallot N, Lopategi A, Gutierrez V, Solaun M, Mendoza L, Vidal-vanaclocha F. Proangiogenic Implications of Hepatic Stellate Cell Transdifferentiation into Myofibroblasts Induced by Tumor Microenvironment. Tissue Repair, Contraction and the Myofibroblast. Boston: Springer US; 2006. pp. 88-101. [DOI: 10.1007/0-387-33650-8_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Plentz RR, Tillmann HL, Kubicka S, Bleck JS, Gebel M, Manns MP, Rudolph KL. Hepatocellular carcinoma and octreotide: Treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage. J Gastroenterol Hepatol 2005;20:1422-8. [DOI: 10.1111/j.1440-1746.2005.03959.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
64 Tsagarakis NJ, Drygiannakis I, Batistakis AG, Kolios G, Kouroumalis EA. Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells. World J Gastroenterol 2011; 17(3): 313-321 [PMID: 21253389 DOI: 10.3748/wjg.v17.i3.313] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
65 Hopp K, Hommerding CJ, Wang X, Ye H, Harris PC, Torres VE. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J Am Soc Nephrol 2015;26:39-47. [PMID: 24994926 DOI: 10.1681/ASN.2013121312] [Cited by in Crossref: 54] [Cited by in F6Publishing: 34] [Article Influence: 7.7] [Reference Citation Analysis]
66 Ortega C, Wong RK, Schaefferkoetter J, Veit-haibach P, Myrehaug S, Juergens R, Laidley D, Anconina R, Liu A, Metser U. Quantitative 68 Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177 Lu-DOTATATE. J Nucl Med 2021;62:1406-14. [DOI: 10.2967/jnumed.120.256727] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol Rev 2018;70:763-835. [PMID: 30232095 DOI: 10.1124/pr.117.015388] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 35.0] [Reference Citation Analysis]
68 Verhoef C, van Dekken H, Hofland L, Zondervan P, de Wilt J, van Marion R, de Man R, Ijzermans J, van Eijck C. Somatostatin Receptor in Human Hepatocellular Carcinomas: Biological, Patient and Tumor Characteristics. Dig Surg 2008;25:21-6. [DOI: 10.1159/000117819] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
69 Jackson AW, Chandrasekharan P, Ramasamy B, Goggi J, Chuang KH, He T, Robins EG. Octreotide Functionalized Nano-Contrast Agent for Targeted Magnetic Resonance Imaging. Biomacromolecules 2016;17:3902-10. [PMID: 27936729 DOI: 10.1021/acs.biomac.6b01256] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
70 Hasskarl J, Kaufmann M, Schmid HA. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Future Oncology 2011;7:895-913. [DOI: 10.2217/fon.11.66] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
71 Turato C, Balasso A, Carloni V, Tiribelli C, Mastrotto F, Mazzocca A, Pontisso P. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma. J Control Release 2017;268:184-97. [PMID: 29051062 DOI: 10.1016/j.jconrel.2017.10.027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
72 Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D, Paraskevas E. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial. World J Gastroenterol 2007; 13(23): 3164-3170 [PMID: 17589893 DOI: 10.3748/wjg.v13.i23.3164] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
73 Lequoy M, Desbois-mouthon C, Wendum D, Gupta V, Blachon J, Scatton O, Dumont S, Bonnemaire M, Schmidlin F, Rosmorduc O, Fartoux L. Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis. Histopathology 2017;70:492-8. [DOI: 10.1111/his.13034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]